Virus-like particle vaccine · VDDBV0283
Note: 7 additional source trials listed this vaccine in studies of unrelated viruses (e.g. as a comparator, adjunct, or in coadministration trials with other vaccines). Those trials are not shown here.
| NCT ID | Phase | Disease / Condition |
|---|---|---|
| NCT03451071 | Approved | Genital Warts; Anal Cancer; Anal Intraepithelial Neoplasia |
| NCT05329961 | Phase 1 | Papillomavirus Infections |
| NCT04206813 | Approved | Papillomavirus Infections |
| NCT03431246 | Phase 3 | Papillomavirus Infections; Uterine Cervical Neoplasms |
| NCT03158220 | Phase 3 | Dengue Fever |
| NCT00943722 | Phase 3 | Papillomavirus Infections; Coronavirus Disease (COVID-19) |
| NCT01047345 | Phase 3 | Papillomavirus Infections |
| NCT01984697 | Phase 3 | Papillomavirus Infections |
| NCT00988884 | Phase 3 | Papilloma Viral Infection |
| NCT01254643 | Phase 3 | Cervical Intraepithelial Neoplasia |
| NCT03903562 | Phase 3 | HPV Infection; CIN 2; 3; Cervical Cancer |
| NCT01073293 | Phase 3 | HPV Infection; Hiv; HPV Vaccine |
| NCT04635423 | Phase 3 | HPV; Immunization; Human Papilloma Virus |
| NCT01824537 | Approved | Idiopathic CD4 T Cell Lymphocytopenia |
| NCT04255849 | Phase 3 | Neoplasia |
| NCT03676101 | Phase 1 | Papillomavirus Vaccines |
| NCT03947775 | Phase 1 | Human Papillomavirus |
| NCT04895020 | Phase 3 | Papillomavirus Vaccines; Human Immunodeficiency Virus; Papillomavirus Infection |
| NCT04311528 | Approved | Papillomavirus Infections |
| NCT03525210 | Phase 3 | HPV Vaccines Immunogenicity and Safety |
| NCT03943875 | Approved | Human Papillomavirus (HPV) Infections; High-risk HPV |
| NCT04422366 | Phase 3 | Allogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm |
| NCT03832049 | Phase 3 | Human Papillomavirus Infection |
| NCT05314023 | Phase 3 | Cervical Cancers; Vulvar Cancer; Vaginal Cancer; Genital Lesions; PAP Test Abnormalities; HPV Infections |
| NCT01651949 | Phase 3 | Cervical Cancers; Vulvar Cancers; Vaginal Cancers; Genital Warts |
| NCT04772534 | Phase 3 | Human Papillomavirus Infection |
| NCT04708041 | Phase 3 | Human Papillomavirus Infection |
| NCT03546842 | Phase 3 | Papillomavirus Infections |
| NCT04313244 | Phase 3 | Papillomavirus Infections |
| NCT05119855 | Phase 3 | Papillomavirus Infections |
| NCT05285826 | Phase 3 | Warts, Genital; Neoplasms, Anal |
| NCT04199689 | Phase 3 | Human Papillomavirus Infection |
| NCT04459221 | Approved | Human Papillomavirus |
| NCT03848039 | Phase 3 | Papilloma Viral Infection |
| NCT04910802 | Approved | Papillomavirus Infections |
| NCT04982614 | Approved | Papillomavirus Infections; Genital Diseases, Female |
| NCT04274153 | Approved | Anogenital Human Papilloma Virus Infection; Condyloma Acuminata |
| NCT03519464 | Phase 2 | Anogenital Human Papilloma Virus Infection; Condyloma Acuminata |
| NCT03979014 | Phase 3 | Cervical Cancer; Cervical Intraepithelial Neoplasia; Adenocarcinoma in Situ |
| NCT03350698 | Approved | Cervical Cancer; Genital Warts |
| NCT02968420 | Approved | Cervical Cancer; Genital Warts |
| NCT05266898 | Approved | Cervical Cancer; Genital Warts |
| NCT03675256 | Approved | Cervical Cancer; Genital Warts |
| NCT02567955 | Phase 3 | Human; Papillomavirus Infections |
| NCT05334706 | Phase 2 | Prevention of HPV Types 16- and 18-related Cervical Cancer |
| NCT03023631 | Approved | Cervical Cancer; Hpv; Warts |
| NCT01304498 | Phase 3 | HPV; HIV |
| NCT02114385 | Phase 3 | Papillomavirus Infections |
| NCT03998254 | Phase 3 | Dose Schedule Study |